integral membrane protein 2AGenealiases: BRICD2A · E25A
Q-omics provides the consensus-scored ITM2A profile across patient tissues and cancer cell-line models. ITM2A expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, ITM2A is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, ITM2A RNA expression shows 23,092 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, BLCA, and LSCC as cancer lineages where ITM2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ITM2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ITM2A survival associations across molecular data types. ITM2A RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ITM2A RNA expression–survival associations across cancer types. High ITM2A expression shows favorable associations in SKCM, KIRC, HNSC, LIHC, CESC and BRCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for ITM2A RNA expression.
This table summarizes ITM2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in BLCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ITM2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ITM2A shows lower tumor expression in BLCA, COAD, HNSC, THCA, LUSC and LUAD. The BLCA box plot shows higher ITM2A RNA expression in normal versus tumor tissue (log2 FC = −3.950, t-test p < 0.001).
This table shows molecular features associated with ITM2A in patient tissues and cancer cell lines. In patient samples, ITM2A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ITM2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BONE and SKIN.
